Chronic AChE inhibition with pyridostigmine prevented the progression of CHF, decreasing chamber wall thinning (↑ PWDd, ↑ PWDs) and dilatation progression (↓ LVIDd, ↓ LVIDs), thus improving cardiac contractile function (↑ EF), which was coupled with a decrease in the serum CHF marker NTproBNP. This evidence concerns the gene ACHE and congestive heart failure.